DLL3 Modulators Targeting Tumor Initiating Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate for certain malignancies, particularly those with gene mutations that render them non-responsive, and there is a challenge in preventing relapse, tumor recurrence, and metastasis, as existing therapies fail to effectively target tumor initiating cells.
Innovation Solution
Development of Delta-like ligand 3 (DLL3) modulators, including anti-DLL3 antibodies and fusion constructs, which target tumor cells and cancer stem cells, used in immunotherapeutic treatments to reduce the frequency of tumor initiating cells and inhibit tumor growth, recurrence, and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional cancer treatments (chemotherapy, radiotherapy, surgery) are used, then general tumor mass can be reduced, but tumor initiating cells remain unaffected leading to relapse and metastasis
Solution Approach 1:
The patent segments the tumor population by identifying and targeting tumor initiating cells (TICs) as a distinct subpopulation from bulk tumor cells. This segmentation allows for selective targeting of TICs through antibodies against surface markers like CD44, CD133, and EpCAM, while bulk tumor cells continue to be addressed by conventional therapies. The segmentation principle resolves the contradiction by enabling differentiated treatment strategies for different tumor cell subsets.
Solution Approach 2:
The patent employs antibody intermediaries that specifically bind to surface markers on tumor initiating cells. These antibodies (e.g., anti-CD44, anti-CD133, anti-EpCAM) serve as mediators that deliver cytotoxic agents selectively to TICs. The intermediary antibodies enable precise targeting of TICs without affecting bulk tumor cells, thereby preventing relapse and metastasis while maintaining the effectiveness of conventional tumor mass reduction therapies.
2Productivity
If conventional treatments are applied, then tumor mass can be reduced, but the therapies lack specificity for tumor initiating cells
Solution Approach 1:
The patent applies local quality by赋予 different therapeutic properties to different cell populations within the tumor. Conventional therapies provide non-specific tumor mass reduction, while the patent introduces locally specific antibody-mediated cytotoxicity targeted at TICs expressing specific surface markers. This local quality differentiation enables precise targeting of TICs with high measurement precision while maintaining overall tumor mass reduction capability.
Solution Approach 2:
The patent changes the targeting parameter from non-specific bulk tumor targeting to specific surface marker expression-based targeting. By identifying TICs through specific surface markers (CD44, CD133, EpCAM) and using antibodies against these markers, the patent transforms the therapy from non-specific to highly specific. This parameter change in targeting specificity enables precise differentiation between TICs and bulk tumor cells, resolving the contradiction between tumor mass reduction and targeting precision.
3Reliability
If new targeted therapies are developed to address treatment failures, then therapy complexity increases, but existing therapies remain insufficient
Solution Approach 1:
The patent merges conventional tumor mass reduction therapies with targeted antibody-mediated TIC elimination. This combination creates a comprehensive therapeutic regimen that addresses both bulk tumor cells and TICs simultaneously. The merging of these two therapeutic approaches enhances reliability by preventing relapse and metastasis through TIC targeting, while the complexity is managed through the use of established conventional therapies combined with the targeted antibody component.
Data Source
AI summary
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.